Iridial pigmentation and eyelash change occurred at a high frequency in long-term treatment with latanoprost in Japanese glaucoma patients.
Aim: To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction in glaucoma patients. Methods: Examination was conducted on 16 eyes of 16 glaucoma patients who had been given only latanoprost for at least 6 weeks. The NSAID ophthalmic solution, sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, was additionally given for 12 weeks into one eye (NSAID group), while sodium hyaluronic acid ophthalmic solution was administered into the other eye (control group) in a double masked fashion. The IOP measurement was performed before the start of additional administration of ophthalmic solutions, 2, 4, 6, 8, 10, and 12 weeks after the start of additional administration, and 2, 4, and 6 weeks after discontinuing additional administration. Results: No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the NSAID group and the control group. Following the additional administration of ophthalmic solution, IOP in the NSAID group was consistently higher than that in the control group, and a maximum difference in IOP between the two groups was 1.08 (SD 1.75) mm Hg (p = 0.03). This trend was observed even after additional administration was discontinued. Conclusion: NSAID ophthalmic solution may partly affect IOP reduction by latanoprost. L atanoprost is a phenyl substituted analogue of prostaglandin F2a (PGF 2a ), and is widely used for the treatment of glaucoma because of its excellent potent intraocular pressure (IOP) reduction. 1-3Although the mechanism of IOP reduction by latanoprost is thought to increase the uveoscleral outflow as a result of remodelling the extracellular matrix of ciliary muscle mediated by FP receptors, the details of this mechanism remain unclear.1 4-6 PGF 2a related drugs have been reported to produce endogenous prostaglandins (PGs), and several reports have suggested that induction of endogenous PGs is involved in IOP reduction. [7][8][9] Although it appears certain that endogenous PGs are produced by administering PGF 2a related drugs based on the results of basic experiments, 7 8 since the action of PG on the eyes shows species differences, the results of basic and animal experiments cannot be directly applied to the human eye.2 Therefore, we have conducted a study on the action of endogenous PGs on IOP resulting from the administration of PGF 2a in healthy volunteers, and found that the IOP reduction of latanoprost is inhibited by the administration of NSAID ophthalmic solution.10 However, there have yet to be studies on the effect of NSAID ophthalmic solution on the IOP reduction of latanoprost in glaucomatous human eyes.In this study, a prospective double blind study was conducted to assess the effect of administering NSAID ophthalmic solution on the IOP reduction of latanoprost, targeting patients with primary open angle glaucoma (POAG) or ocular hypertension (OH). SUBJECTS AND METHODSAll experiments were conducted in accordance...
Br J Ophthalmol 2003;87:956-959 Aim: To compare incidence of iridial pigmentation prospectively induced by long term treatment with latanoprost and isopropyl unoprostone (hereafter, unoprostone) in Japanese patients with glaucoma. Methods: Patients with glaucoma treated with prostaglandin (PG) related ophthalmic solutions were sequentially enrolled. Patients treated for more than 30 months with PG related ophthalmic solutions were subjected to analysis. The entry criteria were no history of intraocular surgery, laser iridotomy, and/or laser trabeculoplasty within 12 months before and after the enrolment; and no history of uveitis; no changes in antiglaucoma drugs within 6 months before and after the enrolment. Photographs of the irides were taken under the same conditions and three glaucoma specialists evaluated the iridial pigmentation with masking of patient information. The correlation of iridial pigmentation with the background factors and the reduction of intraocular pressure (IOP) before and after the treatment were investigated. Results: 48 eyes in 48 patients satisfied the enrolment criteria (25 eyes in the latanoprost group, 23 eyes in the unoprostone group). At the end of the follow up period, iridial pigmentation was present in 15 patients (60.0%) in the latanoprost group and seven patients (30.4%) in the unoprostone group. The correlation between development of iridial pigmentation and age, sex, concurrent use of other ophthalmic solutions, and IOP reduction was not significant. Conclusions: The incidence of iridial pigmentation induced by latanoprost or unoprostone is high in the case of long term treatment. Iridial pigmentation did not affect PG related ophthalmic solution induced IOP reduction.
Systemic arterial stiffness seems not to be strongly associated with glaucoma.
Light sense (foveal sensitivity) is related to spatial resolution (logMAR) at the center of the fovea, in eyes with ERM, RVOME, and CSC at different strengths depending on the disease. Less pronounced reduction of visual acuity compared with foveal sensitivity in eyes with CSC could explain the tendency of these patients to complain of dimness rather than acuity loss.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.